Actively Recruiting
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Led by Javier Toledo · Updated on 2026-01-02
6000
Participants Needed
4
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
CONDITIONS
Official Title
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 40 years or older
- Confirmed diagnosis of Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Ovarian Cancer, or Pancreatic Cancer (Phase 1)
- Adults aged 40 years or older
- Confirmed diagnosis of Hepatocellular Carcinoma or Non-Small Cell Lung Cancer
- Willingness to provide blood samples at baseline, 6 weeks, and 6 months post-therapy initiation (Phase 2)
You will not qualify if you...
- Currently pregnant
- Presence of any active infectious diseases
- Use of anticoagulant or antiplatelet drugs within the past 2 weeks
- Any medical or psychological conditions affecting ability to comply with study procedures
- Presence of another malignancy unless in remission for at least 5 years (Phase 2)
- Significant uncontrolled co-morbid conditions interfering with study participation or outcomes (Phase 2)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Various Cancer Centres
Rosario, Argentina
Active, Not Recruiting
2
NSIA- Lagos University Teaching Hospital Cancer Centre
Lagos, Nigeria
Actively Recruiting
3
Babraham Research Institute
Cambridge, United Kingdom, CB22 3AT
Enrolling by Invitation
4
Dysplasia Diagnostics Limited
London, United Kingdom, W1W 7LT
Actively Recruiting
Research Team
J
Javier Toledo, Medical Degree
CONTACT
O
Osagie Izuogu, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here